ELI-002
Elicio Therapeutics
['rectal', 'colorectal', 'pancreatic', 'elicio', 'elicio,(-delicious)']
elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal cancer at the asco annual meeting - health stocks... 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2